FDA Adds Warning to Veozah Menopause Drug

The U.S. Food and Drug Administration (FDA) said on Sept. 12 that it is adding a warning to Veozah, a drug used to treat hot flashes experienced because of menopause.

Veozah, also known as fezolinetant, “can cause rare but serious liver injury,” the FDA said in an alert.
The FDA added the warning after reviewing a case of serious liver injury in a person who suffered symptoms such as yellow eyes and skin and dark urine within 40 days of starting Veozah.

The symptoms eventually went away after the person stopped using the medicine, and blood test results ultimately returned to normal.

If users of the drug experience any signs or symptoms of liver injury, they should stop taking the medicine, regulators said.

Symptoms include fatigue, nausea, jaundice, dark urine, and abdominal pain.

Read Full Article Here